Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Non-small Cell Lung Cancer (NSCLC): early-phase trial registry
30 of 60 indexed Non-small Cell Lung Cancer (NSCLC) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #235 of 28,707 conditions by registered trial count.
60 US clinical trials · 30 currently recruiting · #235 of 28,707 conditions by registered trial count
Non-small Cell Lung Cancer (NSCLC): 60 US clinical trials tracked, 30 recruiting.
Non-small Cell Lung Cancer (NSCLC) is the subject of 60 registered US clinical trials on ClinicalTrials.gov, 30 of them currently open to new participants. 9 are in Phase 3-4 (later-stage) and 48 in Phase 1-2 (earlier-stage). The most active sponsor is Revolution Medicines, running 7 of these trials.
Enrollment posture brief
Registry condition non-small-cell-lung-cancer-nsclc
OPEN 30 | RECR 50% | LATE 9 | EARLY 48 | RANK #235 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Non-small Cell Lung Cancer (NSCLC) lists 30 open slots (50% of 60 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Non-small Cell Lung Cancer (NSCLC) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Non-small Cell Lung Cancer (NSCLC) is recruiting above its size-band peers.
30 of 60 indexed trials (50%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Non-small Cell Lung Cancer (NSCLC) trials is spread across many organizations.
Revolution Medicines accounts for 7 of 60 trials (11.7%). 43 distinct sponsors appear on at least one study for this condition label.
-
Typical Non-small Cell Lung Cancer (NSCLC) enrolment sits around 209 participants.
Median target enrolment is 209 among the 60 trials that report a genuine target (sentinel values excluded). 23 of those (38.3%) plan for fewer than 100 participants.
-
Non-small Cell Lung Cancer (NSCLC) research is mostly interventional.
59 interventional and 1 observational studies make up this index (98.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
60 total, page 2 of 2
Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer
Stanford University
NCT00323869
A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients
Academic Thoracic Oncology Medical Investigators Consortium
NCT02879617
FDG PET/CT in Lung Cancer Staging
Abramson Cancer Center at Penn Medicine
NCT02738398
Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects
UNC Lineberger Comprehensive Cancer Center
NCT01323062
A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer
Bavarian Nordic
NCT02840994
Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors
University of California, Davis
NCT01336842
Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer
Yale University
NCT00821951
Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer
Syndax Pharmaceuticals
NCT01594398
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration
Incyte Corporation
NCT05253807
Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer
Concordia Laboratories
NCT02916745
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 37 |
| Phase 2 | 11 |
| Phase 3 | 8 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Non-small Cell Lung Cancer (NSCLC) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Non-small Cell Lung Cancer (NSCLC) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Non-small Cell Lung Cancer (NSCLC) page
60 registered trials, 30 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 30 Non-small Cell Lung Cancer (NSCLC) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Revolution Medicines sponsors the most Non-small Cell Lung Cancer (NSCLC) trials on record, review their full trial history before evaluating a specific study. See Revolution Medicines's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Non-small Cell Lung Cancer (NSCLC) condition card totals 60 registered trials; most-linked intervention Pembrolizumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.